One of the main problems at commercial accounting of resources (natural gas, electric energy, heat, water) is discrepancy of registered volumes (quantity) of delivered (supplied) and consumed (paid) resource. Stated treats not only a resource, but also an accounting of deliveries related to any kind of goods which quantity is defined and considered by means of measuring tools (packaging of loose products, supply of gasoline from a plant at a gas station, its further realization to consumers, etc.). It is accepted to call a discrepancy of specified volumes as imbalance. Its consequence is either an incomplete settlement of consumers with a supplier (supplier’s damage and consumers’ “undeserved profit”), or, on the contrary, consumers’ overpayment for delivered resource (supplier’s “undeserved profit” and consumers’ damage). Therefore, the resource imbalance can be classified as one of the most important economic indicators of any resource supplying process since the economic efficiency of activity of companies and organizations delivering and realizing resources to consumers depends directly on the resource imbalance value.

The study involved 24 patients with coronary heart disease (CHD) and chronic heart failure II-IV FC according to NYHA, also the systolic dysfunction of the left ventricle and sinus tachycardia needing surgical myocardial revascularization in EC conditions (extracorporeal circulation). All patients had II-IV functional class (FC) of CHF (chronic heart failure) according to NYHA (average 2,8±0,6). FC of effort angina was 2,6±0,4 (CCS). 92% of patients had a history of myocardial infarction and sinus rhythm. To correct CHF, coronary insufficiency and to prepare for CABG in EC conditions, the drug therapy by means of ACE-inhibitors of angiotensin-receptor blockers, beta- blockers, calcium channel blockers, diuretics, digoxin and aldosterone antagonists was carried out all patients. Average heart rate (HR) at rest was 98±6 per minute. To achieve further normal HR in the drug therapy was added the Ivabradine in the dose of 10-15 mg per day for 18-38 days prior to myocardial revascularization. The use of the Ivabradine in the dose of 13±1 mg per day allows to decrease FC of CHF and coronary insufficiency in the patients with low contractile ability of the myocardium and hemodynamically significant stenosis of coronary arteries and to achieve normal HR in 75 % of patients with good tolerability.

The article studies the procedure of development of Activity Plan on localization and liquidation of accidents consequences on hazardous industrial facilities. It notes ambiguousness of requirements to Plans introduced by Decrees of the Government of the Russian Federation and Recommendations of the Federal Environmental, Engineering & Nuclear Supervision Agency (Rostehnadzor). To provide industrial safety it is recommended to create a single regulatory document in accordance with which all other documentation on localization and liquidation of accidents consequences on hazardous industrial facilities must be developed.

No abstract